Results 51 to 60 of about 3,150 (198)
Nepal Journal of Dermatology, Venereology & Leprology, 2019 Intorduction: Vulval disorders can be of venereal and non-venereal etiology. Establishing non-venereal causation of vulval disorder helps in alleviating fears in patients with the condition.
Smita Joshi +2 more
doaj +3 more sources
Etiology, Clinical Features, and Diagnosis of Vulvar Lichen Sclerosus: A Scoping Review
Obstetrics and Gynecology International, 2020 Objective. Vulvar lichen sclerosus (VLS) is a chronic inflammatory disorder, which affects women of all ages. With numerous controversies as regards to the nomenclature, diagnosis and its association with neoplastic conditions, we decided to conduct a ...
Nilanchali Singh, Prafull Ghatage
doaj +1 more source
Delayed Diagnosis of Sézary Syndrome: Lessons From a Psoriasiform Presentation
Clinical Case Reports, Volume 14, Issue 1, January 2026.ABSTRACT Pruritic erythroderma is not always psoriasis. Resistant cases require a broad evaluation for cutaneous lymphoma. Early, timely diagnosis prevents disease progression, improves outcomes, and enhances quality of life, highlighting the need for re‐evaluation when conventional treatments fail.
Sudhan Neupane +3 more
wiley +1 more source
Tratamento conservador do carcinoma do pênis - estudo retrospectivo de 10 anos [PDF]
, 2013 Conservative treatment of penile squamous cell carcinoma has been advocated as a method of choice for tumours at early stages. Thirty patients with a mean age of 63.2 years were treated with CO2 laser ablation, radical local excision with preputial flap,
Cabral, AR +3 more
core +1 more source
American Journal of Hematology, Volume 100, Issue 9, Page 1603-1628, September 2025.ABSTRACT Disease Overview Primary cutaneous lymphomas are a rare and heterogeneous group of extranodal lymphomas that require the integration of clinical and histopathologic data for classification and treatment. Diagnosis Diagnosis and disease classification is based on histopathologic review and immunohistochemical staining of an appropriate skin ...
Alexandra C. Hristov +2 more
wiley +1 more source
Патогенетичні взаємовідношення між бляшковою склеродермією, атрофодермією Пазіні–П’єріні та склероатрофічним ліхеном [PDF]
, 2015 У 130 хворих на бляшкову склеродермію, склероатрофічний ліхен, атрофодермію констатовані подібні показники порушень імунної системи (CD3, CD4, CD8, CD16, CD22, CD25, CD38, CD95, IgA, IgG, IgM, ЦІК, TNFα, IL-2, IL-4, IL-6, IL-10), адсорбційно-реологічних ...
Горбунцов, В.В. +2 more
core
Trends and Developments in Vulvar Lichen Sclerosus Research
Health Science Reports, Volume 8, Issue 7, July 2025.ABSTRACT Background Despite the prevalence of vulvar lichen sclerosus (VLS) as a chronic skin disease in clinical settings, there is a notable absence of a comprehensive bibliometric analysis summarizing the existing literature on this topic. The aim of this study is to offer clinicians, researchers, and other interested parties an up‐to‐date overview ...
Fan‐Rong He +3 more
wiley +1 more source
Infantile Perianal Pyramidal Protrusion: A Report of 8 New Cases and a Review of the Literature
Case Reports in Dermatology, 2012 Infantile perianal pyramidal protrusion (IPPP) is characterized by a protrusion located most often anterior to the anus. Three types of IPPPs are recognized: (a) constitutional, (b) acquired (mainly due to constipation), and (c) IPPPs due to lichen ...
N. Zavras +3 more
doaj +1 more source
Surgical treatment of Paget’s disease of the vulva using Mohs micrographic surgery, followed by vulvar reconstruction using the “lotus petal” suprafascial flap [PDF]
, 2016 Vulvar Paget’s disease is an extramammary manifestation of Paget’s disease, a cutaneous neoplasm that clin-ically appears as sharply defined erythematous plaques with irregular borders that usually affect apocrine gland-bearing skin. Extramammary Paget’s
Herraiz Roda, José Luis +5 more
core +3 more sources
Experimental Dermatology, Volume 34, Issue 4, April 2025.ABSTRACT JAK inhibitors are used to treat various inflammatory skin diseases. However, systemic formulations are associated with an increased risk of major adverse events. Ruxolitinib 1.5% cream is a selective topical JAK1 and JAK2 inhibitor, which has recently been approved by EMA and MHRA for treating non‐segmental vitiligo, while being FDA‐approved ...
Marco Spadafora +5 more
wiley +1 more source